Cameron Britton, MD, discusses clinical outcomes with the MyProstateScore 2.0 assay

Data presented at the 2025 Society of Urology Oncology Annual Meeting in Phoenix, Arizona, suggest that the MyProstateScore 2.0 (MPS2), a novel non-DRE urine test, may be able to accurately guide management strategies for patients who are on active surveillance for grade group 1 prostate cancer.¹ Specifically, data showed that the MPS2 test was able to detect 95% of grade group 3 or higher cancers while avoiding 70% of unnecessary biopsies in these patients.

In an interview with Urology Times®, presenting author Cameron J. Britton, MD, broke down the key findings from the study and the potential implications of these results for clinical care. Britton is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.

REFERENCE

1. Britton CJ, Chevli K, Rayford W, et al. MyProstateScore 2.0 urine test accurately determines the need for biopsy in patients on active surveillance for grade group 1 prostate cancer. Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2025; Phoenix, Arizona. Abstract 180. https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4849